TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05599945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0581-0001
Description: Participants will receive up to six single dose levels of subcutaneous NNC0581-0001 in a sequential manner with the dose increasing between cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0581-0001
Description: Participants will receive up to six single dose levels of subcutaneous NNC0581-0001 in a sequential manner with the dose increasing between cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0581-0001
Description: Participants will receive up to six single dose levels of subcutaneous NNC0581-0001 in a sequential manner with the dose increasing between cohorts.
Study: NCT05352646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous memory lymphocyte Injection (NewishT), high-dose group
Description: Recruited participants in high-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 2 weeks, a total of 4 times.
Study: NCT05599945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0581-0001
Description: Participants will receive up to six single dose levels of subcutaneous NNC0581-0001 in a sequential manner with the dose increasing between cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0581-0001
Description: Participants will receive up to six single dose levels of subcutaneous NNC0581-0001 in a sequential manner with the dose increasing between cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0581-0001
Description: Participants will receive up to six single dose levels of subcutaneous NNC0581-0001 in a sequential manner with the dose increasing between cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0581-0001)
Description: Participants will receive single dose of subcutaneous injection of placebo matched to NNC0581-0001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0581-0001)
Description: Participants will receive single dose of subcutaneous injection of placebo matched to NNC0581-0001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0581-0001)
Description: Participants will receive single dose of subcutaneous injection of placebo matched to NNC0581-0001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0581-0001)
Description: Participants will receive single dose of subcutaneous injection of placebo matched to NNC0581-0001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0581-0001)
Description: Participants will receive single dose of subcutaneous injection of placebo matched to NNC0581-0001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0581-0001)
Description: Participants will receive single dose of subcutaneous injection of placebo matched to NNC0581-0001.
Study: NCT05573230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Administered orally.
Study: NCT05726032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.
Study: NCT05418829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-007
Description: AT-007 20 mg/kg once daily
Study: NCT06400940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).
Description: Antiplatelet (antithrombotic) monotherapy, including ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).
Description: Double antiplatelet (antithrombotic) therapy (DAT), including a combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).
Study: NCT04192019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micro-glucagon
Description: Administration of 80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mini-glucagon
Description: Administration of 150 µg (mini-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
Study: NCT05746364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief CAT-Informed Intervention for Young People experiencing Difficulties with Eating
Description: The therapy draws upon the principles of Cognitive Analytic Therapy (CAT), focussing on collaboratively identifying relational patterns (relationships with self and others) that young people experience difficulties with. The young person will be invited to attend 5 weekly sessions, each lasting 30-50 minutes. It will be delivered within a seven-week window (allowing for cancellations/missed sessions). Researchers will follow the RIDE manual treatment guide, which was developed by Clinical Psychologists, CAT accredited therapists and researchers.
Study: NCT05770518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Biofeedback is a strategy used in the treatment of PVFM, which involves allowing patients to directly visualize their breathing patterns during laryngoscopy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal control therapy (LCT)
Description: This treatment typically involves 2 guided therapy sessions that include patient education, relaxation techniques, and training in specific breathing techniques.
Study: NCT04831710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab,200mg, ivd, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide,30mg,po,biw,d1-21
Study: NCT05880901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After school program
Description: The after school program are existing community-based programs that take place immediately after the regular school day (typically 3:00-6:00pm); are located in a school; are available daily throughout the academic year (Monday through Friday); and provide a combination of scheduled activities, which include a snack, homework assistance/tutoring, enrichment activities (e.g., arts and crafts, music), and opportunities for children to be physically active.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After school program
Description: The after school program are existing community-based programs that take place immediately after the regular school day (typically 3:00-6:00pm); are located in a school; are available daily throughout the academic year (Monday through Friday); and provide a combination of scheduled activities, which include a snack, homework assistance/tutoring, enrichment activities (e.g., arts and crafts, music), and opportunities for children to be physically active.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Summer day camp
Description: The summer day camp programs are existing camps which take place at schools from which children will be recruited. The camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Summer day camp
Description: The summer day camp programs are existing camps which take place at schools from which children will be recruited. The camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks.
Study: NCT05438628

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound
Description: Measurement of thickness of rectus abdominis, biceps brachii muscles
Study: NCT06571565

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: Conservative treatment will be applied to the back-neck region in both groups. In this treatment, 20 min hotpack, 10 min ultrasound agent (frequency 0.5-3.5MHz), 20 min Transcutaneous Electrical Nerve Stimulation (TENS) agent (Conventional TENS; Frequency 60-80 Hz, current passage time 50-100 microseconds) will be given.
Study: NCT05827848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous peripheral nerve stimulation system
Description: All subjects underwent a 7-day baseline assessment (VAS score for at least 4 days) during the screening/baseline period. Eligible subjects underwent PNS surgery and implanted electrode leads and entered the 7-day test period. During the test period, subjects with an average VAS score improvement of ≥30%(VAS score for at least 4 days) will be randomly assigned to the experimental group (on state) or the control group (off state) in a 1:1 ratio for 7 days observation. All subjects were enrolled in the observation period until 28 days after implantation. Safety assessment was performed at a 14-day follow-up after removal of the device.
Study: NCT06571565

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: Conservative treatment will be applied to the back-neck region in both groups. In this treatment, 20 min hotpack, 10 min ultrasound agent (frequency 0.5-3.5MHz), 20 min Transcutaneous Electrical Nerve Stimulation (TENS) agent (Conventional TENS; Frequency 60-80 Hz, current passage time 50-100 microseconds) will be given.
Study: NCT05307393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positioning
Description: Upon admission to labor and delivery, following an initial ultrasound to confirm fetal OP position, women in this study will be randomly assigned to one of three groups; one control (Group A), and two experimental (Groups B and C) groups. Those assigned to Group A will be allowed to remain in any position they chose during their labor and delivery course. Group B will be placed in a dorsal recumbent, modified sims position on the side of fetal movement. Group C, will be placed in the same position but opposite that of which fetal kicks are felt.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positioning
Description: Upon admission to labor and delivery, following an initial ultrasound to confirm fetal OP position, women in this study will be randomly assigned to one of three groups; one control (Group A), and two experimental (Groups B and C) groups. Those assigned to Group A will be allowed to remain in any position they chose during their labor and delivery course. Group B will be placed in a dorsal recumbent, modified sims position on the side of fetal movement. Group C, will be placed in the same position but opposite that of which fetal kicks are felt.
Study: NCT06201104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient empowerment education
Description: After the pre-test is administered to the patients in the experimental group, patient empowerment training (intervention) will be given. Patients will be divided into groups of 15 people and the training will be given in a total of 6 sessions, all in one session. The Patient Empowerment Handbook prepared by the researchers will be used during the training. The training was planned to last 1 hour (45 minutes of theoretical training, 15 minutes of question and answer). The training was planned to be carried out in an interactive manner (question and answer method, sharing of patient experiences, group discussion). The Patient Empowerment Handbook will be delivered to patients after the training for them to read whenever they want. How to use the manual will be explained to patients.
Study: NCT05773742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-volume irrigation
Description: Qufora IrriSedo MiniGo
Study: NCT05031767

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Conventional follow-up strategy with blood tests, patient-reported outcomes, and pre-scheduled visits at the hospital every 6th month.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Description: Hospital health professionals perform remote monitoring of frequent patient-reported outcomes, blood test results, and physical activity data available on a digital platform.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-initiated care
Description: No pre-scheduled visits or remote monitoring.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital.
Study: NCT04937790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core stabilization group(CSG)
Description: Exercises training of this group occurs from 3 stages. In the stage 1 covering the first two weeks, core stabilization exercises are going to be applied 3 sets of 10 repetitions except side plank. Side plank is going to be performed 3 sets of 10 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, exercises are going to be performed 3 sets of 12 repetitions except bride dog, plank and side plank. These exercises are going to be applied 3 sets of 15 seconds. Patients are going to perform exercises of stage 3 from 6 to 8 weeks. Exercises of stage 3 are going to be practiced 3 sets of 15 repetitions except bride dog, side plank and plank exercises which are going to be applied 3 set of 20 second. All stages include the same exercises except modified push-up exercise includes instead of plank exercise in stage 1. All of the exercises are going to practiced 3 days a week for 8 weeks. One of the sessions is estimated to take approximately 45-60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wobble board group (WBG)
Description: Patients in this group are going to perform exercise on computerized wobble board. This device is going to provide unstable surface to patient and offer visual feedback about their movement qualities. The 8 weeks program consists of 3 stages and each stage includes six exercises. In the first stage covering the first two weeks, repetitive exercises are going to be practiced 3 sets of 10 repetitions; time controlled exercises are going to be practiced 3 sets of 20 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, repetitive exercises are going to be performed 3 sets of 12 repetition and time controlled exercises are going to be performed 3 sets of 25 seconds. Stage 3 is going to last from 6 to 8 weeks. In this stage, repetitive exercises are going to be practiced 3 sets of 15 repetitions and time controlled exercises are going to be practiced 3 sets of 30 seconds. One of the sessions is estimated to take approximately 45-60 minutes.
Study: NCT06340282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Immersive virtual reality

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Immersive virtual reality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multicomponent exercise
Description: individualized exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multicomponent exercise
Description: individualized exercise
Study: NCT06306131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel 0.15 milligram
Description: The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam 15 milligram
Description: The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: calcium carbonate 750 milligram
Description: The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).
Study: NCT05978115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant supported prosthesis
Description: Group A: short dental implant placement + Removable partial denture Group B: Short implant placement + Fixed partial denture Group c: Bone Augmentation + Implant placement + Fixed Partial denture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant supported prosthesis
Description: Group A: short dental implant placement + Removable partial denture Group B: Short implant placement + Fixed partial denture Group c: Bone Augmentation + Implant placement + Fixed Partial denture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant supported prosthesis
Description: Group A: short dental implant placement + Removable partial denture Group B: Short implant placement + Fixed partial denture Group c: Bone Augmentation + Implant placement + Fixed Partial denture
Study: NCT05033431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab
Description: Participants will receive IV or SC injection of brazikumab as per the group they are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab
Description: Participants will receive IV or SC injection of brazikumab as per the group they are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab
Description: Participants will receive IV or SC injection of brazikumab as per the group they are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab
Description: Participants will receive IV or SC injection of brazikumab as per the group they are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab
Description: Participants will receive IV or SC injection of brazikumab as per the group they are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab
Description: Participants will receive IV or SC injection of brazikumab as per the group they are assigned.
Study: NCT05388799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: In addition to standard care, brochure-supported education will be given to patients who are scheduled for nose surgery.
Study: NCT05090254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment algorithms targeting cardiac output
Description: Treatment algorithms targeting maximization or personalization of cardiac output

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment algorithms targeting cardiac output
Description: Treatment algorithms targeting maximization or personalization of cardiac output
Study: NCT05301439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration with Resin
Description: Prophylaxis with prophylactic paste and rubber cup. Relative isolation (lip retractor, cotton roll and saliva sucker). Selective removal of carious tissue with dentin spoons at the dentin-enamel junction.~Cleaning the cavity with water. Application of the Universal Adhesive System (Shofu). Excess removal. Application of a new layer of adhesive system. Light rubbing and excess removal. Photoactivation - 20s. Insert Bulk Fill Resin (Shofu) in 4mm increments. Photoactivation for 20. Preservation. Clinical and radiographic control at 1, 3, 6 and 12 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hall Technique
Description: Prophylaxis with prophylactic paste and rubber cup. Relative isolation (lip retractor, cotton roll and saliva sucker). Clinical evaluation through inspection of the texture of the remaining dentin with a rounded exploratory probe.~Cleaning the cavity with water. Take drying. Proof of the steel crown. Relative isolation. Filling the inner part of the crown with bioactive resin cement or glass ionomer cement for cementation.~Clinical and radiographic control at 1, 3, 6 and 12 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Steel Crown
Description: * Prophylaxis;~* Relative isolation;~* The preparation of the tooth will be performed conventionally with reduction of the occlusal, mesial and distal surface of 1 to 1.5 mm and selective removal of the decayed tissue;~* Cleaning the cavity with water;~* Slight drying;~* Trial of steel crown;~* Relative isolation;~* Filling the inner part of the crown with bioactive resin cement or glass ionomer cement for cementation.~* Clinical and radiographic control at 1, 3, 6 and 12 months.